“Oral Anticoagulant Therapy After Atrial Fibrillation Ablation: Risks and Benefits Vary with CHADS2 Score”

https://pubmed.ncbi.nlm.nih.gov/38117227

The study found that continuing oral anticoagulant therapy after atrial fibrillation catheter ablation has differing benefits and risks based on a patient’s CHADS2 score, with the risk of major bleeding outweighing the reduction in thromboembolism for patients with lower thromboembolic risk.